Free Trial
NASDAQ:LXRX

Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis

Lexicon Pharmaceuticals logo
$0.46 +0.00 (+0.72%)
Closing price 04/1/2025 04:00 PM Eastern
Extended Trading
$0.46 +0.00 (+0.19%)
As of 04/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lexicon Pharmaceuticals Stock (NASDAQ:LXRX)

Key Stats

Today's Range
$0.44
$0.54
50-Day Range
$0.29
$0.99
52-Week Range
$0.28
$2.45
Volume
27.29 million shs
Average Volume
6.01 million shs
Market Capitalization
$114.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.67
Consensus Rating
Hold

Company Overview

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Remove Ads

Lexicon Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

LXRX MarketRank™: 

Lexicon Pharmaceuticals scored higher than 66% of companies evaluated by MarketBeat, and ranked 357th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lexicon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lexicon Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Lexicon Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Lexicon Pharmaceuticals are expected to grow in the coming year, from ($0.66) to ($0.45) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lexicon Pharmaceuticals is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lexicon Pharmaceuticals is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lexicon Pharmaceuticals has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Lexicon Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    17.11% of the float of Lexicon Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Lexicon Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Lexicon Pharmaceuticals has recently decreased by 17.28%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Lexicon Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Lexicon Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.11% of the float of Lexicon Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Lexicon Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Lexicon Pharmaceuticals has recently decreased by 17.28%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Lexicon Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Lexicon Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    25 people have searched for LXRX on MarketBeat in the last 30 days. This is an increase of 127% compared to the previous 30 days.
  • MarketBeat Follows

    23 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 360% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.80% of the stock of Lexicon Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    74.70% of the stock of Lexicon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lexicon Pharmaceuticals' insider trading history.
Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Stock News Headlines

A market crash is coming—here’s when
The stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.
Lexicon stock soars on Novo Nordisk licensing deal
See More Headlines

LXRX Stock Analysis - Frequently Asked Questions

Lexicon Pharmaceuticals' stock was trading at $0.7385 at the beginning of the year. Since then, LXRX shares have decreased by 37.2% and is now trading at $0.4641.
View the best growth stocks for 2025 here
.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its earnings results on Thursday, March, 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. The biopharmaceutical company earned $26.55 million during the quarter, compared to analyst estimates of $6.48 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative trailing twelve-month return on equity of 107.38%.

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Moderna (MRNA).

Company Calendar

Last Earnings
3/06/2025
Today
4/01/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:LXRX
Previous Symbol
NASDAQ:LEXG
Employees
140
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$3.67
High Stock Price Target
$6.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+690.1%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-177,120,000.00
Net Margins
-4,109.41%
Pretax Margin
-4,138.33%

Debt

Sales & Book Value

Annual Sales
$31.08 million
Price / Cash Flow
N/A
Book Value
$0.38 per share
Price / Book
1.22

Miscellaneous

Free Float
229,493,000
Market Cap
$114.28 million
Optionable
Optionable
Beta
1.04

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:LXRX) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners